Views & Analysis Novo Nordisk: survival of the fittest applies in diabetes an... Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers.
News Novo hopes hypoglycaemia data will boost Tresiba Lower severe hypo risk compared with Lantus - but no cardiac benefit.
News AZ’s Bydureon disappoints in diabetes outcomes trial Results give advantage to Boehringer/Lilly's Jardiance.
News Semaglutide could transform diabetes treatment, revive Novo ... Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems
News Novo Nordisk board member quits over NASH conflict of intere... Mary Szela has quit to avoid a conflict of interest.
News Third Rock in $2bn drug-hunting pact with China's Funnel New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
